TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Martine Piccart-Gebhart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.